Return-path: <>
Envelope-to: lbaez@edenetsa.com
Delivery-date: Mon, 03 Nov 2014 23:14:45 -0400
Received: from [50.45.95.59] (port=18136 helo=ccaonline-95-59.ccaonline.com)
	by host8.dnns.net with smtp (Exim 4.82)
	id 1XlUZw-0005aM-UC
	for lbaez@edenetsa.com; Mon, 03 Nov 2014 23:14:45 -0400
Received: from unknown (HELO localhost) (branch.support@packeteer.com@69.48.33.130)
	by ccaonline-95-59.ccaonline.com with ESMTPA; Mon, 3 Nov 2014 21:18:27 -0600
From: branch.support@packeteer.com
To: lbaez@edenetsa.com
Subject: Listen Up

"Oncolytics Biotech" Biotechnology Company is focused on the development of 
oncolytic viruses for their further use in the treatment of various forms 
of tumors. The top company's product - "REOLYSIN" - is currently in the 
final stage of clinical testings against cancer of head and neck. The 
medicine's action is based on the reovirus (Respiratory Enteric Orphan 
virus) ability to determine and "infect" the cells with the mutated RAS 
gene. After mutation the gene transforms an ordinary cell into a cancer 
one. "REOLYSIN", developed by the Canadian company "Oncolytics Biotech 
Inc", not only finds the cancer cells with the mutated gene, but is also 
cytocidal. Given that 2/3 of tumors have cells with the mutated RAS gene, 
it is hoped that complex and even propagating tumors might be cured without 
radiation and chemotherapy.

According to recent data, the use of the reovirus medicine in combination 
with chemotherapeutic treatment increases the proportion of fortunate 
result for the treatment of the head and neck cancer up to 74%.

"Oncolytics Biotech Inc (ONCY)" Company's shares are available on NASDAQ 
since 2001, Market Cap 72.36M, rated by Zacks "Strong Buy". As of the end 
of trading on 03/11/2014, the stock price was $0.88, which is a favorable 
entry point for investing in new emerging technologies.

Let us recall that "Oncolytics Biotech Inc" Company was founded in Calgary 
in 1998 in response to developments made on the oncolytic potential of 
reovirus at the University of Calgary in the 1990s. In 1999-2000 the 
company transitioned from private to public ownership. 

The firm was granted its first Canadian patent in August 2000, and at 
present holds more than 200 patents across the globe, including 38 U.S. and 
11 Canadian patents.